Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: mike head who wrote (79)	5/31/1998 9:37:00 PM
From: Arthur Radley	Respond to of 626

I think Titan is trying to use their LIMITED funding wisely and probably staffing is one way. However, as opposed to many start-up biotechs, TTNP is taking the approach to obtain their products through in-licensing from corporate and academic sources. Examples: Iloperidone...Hoechst Spheramine..............New York University CeaVac,TriAb, TriGem....Un. of Kentucky RB94....................Baylor College of Medicine(here in Houston) It is my assumption that since these products have gone through preliminary testing....toxicity and efficacy, this helps avoid a lot of staffing to get products to this stage of approval. IMO it is crucial that they get Iloperidone approved so that they will have a steady stream of royalty coming in, so that they can maintain their efforts with the various products. My hopes for TTNP lies with the broad diversity of their POTENTIAL products. The two main areas that they are concentrating, certainly offers the potential for success in a big way. They only have to provide the "goods".